Page last updated: 2024-12-09

[4-amino-3-(4-methylphenyl)-2-sulfanylidene-5-thiazolyl]-(4-morpholinyl)methanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

You're asking about a very specific chemical compound, **[4-amino-3-(4-methylphenyl)-2-sulfanylidene-5-thiazolyl]-(4-morpholinyl)methanone**. It's a complex molecule with a long chemical name, and it's not something that's widely known or studied.

To understand its potential importance, we need to break it down and consider its structural features:

* **Thiazole Ring:** The compound contains a thiazole ring, which is a heterocyclic ring system with nitrogen and sulfur atoms. Thiazoles are found in many biologically active compounds, including antibiotics, antifungals, and anti-inflammatory agents.
* **Aromatic Groups:** It has an aromatic ring (phenyl, containing a methyl group) attached to the thiazole ring. Aromatic systems are often associated with biological activity.
* **Sulfanilide Moiety:** The sulfanylidene part hints at a sulfanilide group, which is a known pharmacophore (structure associated with biological activity) found in many drugs, like sulfonamides.
* **Amide Linker:** The compound has an amide linkage, which is a common structural feature in many drugs and is involved in binding to biological targets.

**However, without additional information, it's impossible to say why this specific compound is important for research.** Here's why:

* **It's not a known drug or research chemical:** It's highly likely that this molecule has not been synthesized or studied extensively. It might be a hypothetical compound, an intermediate in a chemical synthesis, or a specific target for a particular research project.
* **We need context:** To understand its significance, we need to know the research context:
* **What is the intended application?** Is it being investigated for potential medicinal properties, as a catalyst, or for other uses?
* **Who is researching it?** Is it a pharmaceutical company, a research lab, or an individual scientist?

**To learn more, you would need to:**

1. **Find the research paper or publication where this compound is mentioned.** The name of the compound should be used as a search term in scientific databases like PubMed, Scopus, or Google Scholar.
2. **Reach out to the researchers involved in the project.** They would be the best source of information about the importance and rationale behind investigating this specific compound.

Without more context, it's difficult to determine the significance of this particular molecule.

Cross-References

ID SourceID
PubMed CID891289
CHEMBL ID1391676
CHEBI ID117165

Synonyms (30)

Synonym
OPREA1_267128
morpholine, 4-((4-amino-2,3-dihydro-3-(4-methylphenyl)-2-thioxo-5-thiazolyl)carbonyl)-
4-((4-amino-2,3-dihydro-3-(4-methylphenyl)-2-thioxo-5-thiazolyl)carbonyl)morpholine
brn 1223645
smr000072798
MLS000089115 ,
4-amino-3-(4-methylphenyl)-5-(4-morpholinylcarbonyl)-1,3-thiazole-2(3h)-thione
CHEBI:117165
MLS-0046401.0001
[4-amino-3-(4-methylphenyl)-2-thioxo-2,3-dihydro-1,3-thiazol-5-yl](morpholin-4-yl)methanone
STK877254
AKOS000348763
57037-01-1
[4-amino-3-(4-methylphenyl)-2-sulfanylidene-1,3-thiazol-5-yl]-morpholin-4-ylmethanone
HMS2461K16
(4-amino-2-thioxo-3-(p-tolyl)-2,3-dihydrothiazol-5-yl)(morpholino)methanone
F3222-3036
4-amino-3-(4-methylphenyl)-5-(morpholine-4-carbonyl)-2,3-dihydro-1,3-thiazole-2-thione
[4-amino-3-(4-methylphenyl)-2-sulfanylidene-5-thiazolyl]-(4-morpholinyl)methanone
[4-azanyl-3-(4-methylphenyl)-2-sulfanylidene-1,3-thiazol-5-yl]-morpholin-4-yl-methanone
[4-amino-3-(p-tolyl)-2-thioxo-4-thiazolin-5-yl]-morpholino-methanone
bdbm34472
cid_891289
CHEMBL1391676
Q27203795
SR-01000263314-1
sr-01000263314
Z204242748
DTXSID20972518
[4-amino-3-(4-methylphenyl)-2-sulfanylidene-2,3-dihydro-1,3-thiazol-5-yl](morpholin-4-yl)methanone
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
morpholinesAny compound containing morpholine as part of its structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (20)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency19.95260.044717.8581100.0000AID485294
Chain A, HADH2 proteinHomo sapiens (human)Potency5.79250.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency5.79250.025120.237639.8107AID886; AID893
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency56.23410.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
15-lipoxygenase, partialHomo sapiens (human)Potency19.95260.012610.691788.5700AID887
TDP1 proteinHomo sapiens (human)Potency11.22020.000811.382244.6684AID686979
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency3.16230.011212.4002100.0000AID1030
regulator of G-protein signaling 4Homo sapiens (human)Potency79.43280.531815.435837.6858AID504845
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency0.70790.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency3.98110.035520.977089.1251AID504332
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency10.00000.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
huntingtin isoform 2Homo sapiens (human)Potency2.81840.000618.41981,122.0200AID1688
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency15.00300.168316.404067.0158AID720504
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency14.12540.00419.962528.1838AID2675
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency28.18380.251215.843239.8107AID504327
Guanine nucleotide-binding protein GHomo sapiens (human)Potency5.01191.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
dual specificity protein phosphatase 3Homo sapiens (human)IC50 (µMol)100.00000.40009.361090.0000AID2684
tyrosine-protein phosphatase non-receptor type 7 isoform 2Homo sapiens (human)IC50 (µMol)100.00000.100012.726563.0000AID2678
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]